Last 12 months
Inside the activity.
2 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 1 | 1 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 1 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 23, 2024 Filed Jan 25, 2024 23:24 UTC |
Lurker NancyDirector · Executive Vice Chair
|
SaleCommon Stock | 5,044 | $24.97 | $125,949.69 |
DisclosureSEC source: 0001562180-24-000636 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 165,397 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.95 to $25.00. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 23:26 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,039 | $0.00 Strike: $12.90 | $0.00 |
DisclosureSEC source: 0001562180-24-000637 · primarydocument.xml · derivative · entry 10 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,586 Underlying: Common Stock · 2,039 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020 Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 23:26 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,096 | $0.00 Strike: $13.13 | $0.00 |
DisclosureSEC source: 0001562180-24-000637 · primarydocument.xml · derivative · entry 9 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,204 Underlying: Common Stock · 3,096 shares Expires 2031-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2021 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 23:26 UTC |
Paggiarino Dario A.Chief Medical Officer
|
SaleCommon Stock | 3,096 | $25.00 | $77,400.00 |
DisclosureSEC source: 0001562180-24-000637 · primarydocument.xml · nonDerivative · entry 4 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,505 Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 23:26 UTC |
Paggiarino Dario A.Chief Medical Officer
|
SaleCommon Stock | 2,039 | $25.00 | $50,975.00 |
DisclosureSEC source: 0001562180-24-000637 · primarydocument.xml · nonDerivative · entry 3 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,601 Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 23:26 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Exercise / conversionCommon Stock | 2,039 | $12.90 | $26,303.10 |
DisclosureSEC source: 0001562180-24-000637 · primarydocument.xml · nonDerivative · entry 2 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,640 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 23:26 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Exercise / conversionCommon Stock | 3,096 | $13.13 | $40,650.48 |
DisclosureSEC source: 0001562180-24-000637 · primarydocument.xml · nonDerivative · entry 1 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 16:50 UTC |
Jones David ScottSVP & Chief Commercial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 28,750 | $0.00 Strike: $10.13 | $0.00 |
DisclosureSEC source: 0001562180-24-000581 · primarydocument.xml · derivative · entry 10 Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 28,750 shares Expires 2032-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 16:50 UTC |
Jones David ScottSVP & Chief Commercial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,416 | $0.00 Strike: $11.47 | $0.00 |
DisclosureSEC source: 0001562180-24-000581 · primarydocument.xml · derivative · entry 9 Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,584 Underlying: Common Stock · 5,416 shares Expires 2031-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at November 1st, 2022 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 16:50 UTC |
Jones David ScottSVP & Chief Commercial Officer
|
SaleCommon Stock | 28,750 | $22.69 | $652,254.13 |
DisclosureSEC source: 0001562180-24-000581 · primarydocument.xml · nonDerivative · entry 4 Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,962 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $23.04. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 16:50 UTC |
Jones David ScottSVP & Chief Commercial Officer
|
SaleCommon Stock | 5,416 | $22.24 | $120,437.22 |
DisclosureSEC source: 0001562180-24-000581 · primarydocument.xml · nonDerivative · entry 3 Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,712 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $23.00. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 16:50 UTC |
Jones David ScottSVP & Chief Commercial Officer
|
Exercise / conversionCommon Stock | 5,416 | $11.47 | $62,121.52 |
DisclosureSEC source: 0001562180-24-000581 · primarydocument.xml · nonDerivative · entry 2 Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 16:50 UTC |
Jones David ScottSVP & Chief Commercial Officer
|
Exercise / conversionCommon Stock | 28,750 | $10.13 | $291,237.50 |
DisclosureSEC source: 0001562180-24-000581 · primarydocument.xml · nonDerivative · entry 1 Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 11, 2024 Filed Jan 11, 2024 21:00 UTC |
Cormorant Asset Management, LP10% owner
Chen Bihua10% owner
|
PurchaseCommon Stock | 750,000 | $19.75 | $14,812,500.00 |
DisclosureSEC source: 0000929638-24-000081 · form4.xml · nonDerivative · entry 2 Cormorant Asset Management, LP · CIK 0001583977 · 10% owner Chen Bihua · CIK 0001599214 · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 6,893,235 F1 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. Read SEC document |
| January 11, 2024 Filed Jan 16, 2024 23:55 UTC |
Ocumension TherapeuticsDirector
|
Salecommon stock | 1,910,500 | $19.45 | $37,159,225.00 |
DisclosureSEC source: 0001840315-24-000002 · primary_doc.xml · nonDerivative · entry 1 Ocumension Therapeutics · CIK 0001840315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,221 F1 · date: T+2 settlement on Jan 16 Read SEC document |
| January 11, 2024 Filed Jan 16, 2024 23:01 UTC |
Liu YeDirector
|
SaleCommon Stock, $0.001 par value | 1,910,500 | $19.45 | $37,159,225.00 |
DisclosureSEC source: 0001562180-24-000466 · primarydocument.xml · nonDerivative · entry 1 Liu Ye · CIK 0001840407 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Ocumension Therapeutics Disclosed balance after: 100,221 F1 · ownership.nature: The shares are held by Ocumension Therapeutics. The reporting person is Chief Executive Officer and a Director of Ocumension Therapeutics. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 21:00 UTC |
Cormorant Asset Management, LP10% owner
Chen Bihua10% owner
|
PurchaseCommon Stock | 105,000 | $21.32 | $2,238,600.00 |
DisclosureSEC source: 0000929638-24-000081 · form4.xml · nonDerivative · entry 1 Cormorant Asset Management, LP · CIK 0001583977 · 10% owner Chen Bihua · CIK 0001599214 · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 6,143,235 F2 · price: Represents the weighted average sale price of Common Stock (the "shares") purchased in a series of open market transactions on the transaction date at prices ranging from $20.90 to $21.50 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund. F1 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:53 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 22,913 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001562180-24-000414 · primarydocument.xml · derivative · entry 3 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,742 Underlying: Common Stock · 22,913 shares Expires 2033-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:53 UTC |
Paggiarino Dario A.Chief Medical Officer
|
SaleCommon Stock | 22,913 | $21.13 | $484,124.19 |
DisclosureSEC source: 0001562180-24-000414 · primarydocument.xml · nonDerivative · entry 2 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,505 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.54 to $21.94. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:53 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Exercise / conversionCommon Stock | 22,913 | $3.26 | $74,696.38 |
DisclosureSEC source: 0001562180-24-000414 · primarydocument.xml · nonDerivative · entry 1 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,418 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2024 Filed Jan 9, 2024 21:09 UTC |
Jones David ScottSVP & Chief Commercial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 15,285 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000399 · primarydocument.xml · derivative · entry 5 Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,570 Underlying: Common Stock · 15,285 shares Expires 2033-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning January 6, 2024. Read SEC document |
| January 06, 2024 Filed Jan 9, 2024 21:09 UTC |
Jones David ScottSVP & Chief Commercial Officer
|
Tax withholdingCommon Stock | 4,147 | $20.40 | $84,598.80 |
DisclosureSEC source: 0001562180-24-000399 · primarydocument.xml · nonDerivative · entry 2 Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,962 F2 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| January 06, 2024 Filed Jan 9, 2024 21:09 UTC |
Jones David ScottSVP & Chief Commercial Officer
|
Exercise / conversionCommon Stock | 15,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000399 · primarydocument.xml · nonDerivative · entry 1 Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,109 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,691 shares acquired on July 31, 2023 pursuant to EyePoint's 2019 Employee Stock Purchase Plan. Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 02:17 UTC |
Lurker NancyDirector · Executive Vice Chair
|
Exercise / conversionRestricted Stock Units · Derivative | 75,133 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000402 · primarydocument.xml · derivative · entry 5 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,267 Underlying: Common Stock · 75,133 shares Expires 2033-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning January 6, 2024. Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 02:17 UTC |
Lurker NancyDirector · Executive Vice Chair
|
Tax withholdingCommon Stock | 23,043 | $20.40 | $470,077.20 |
DisclosureSEC source: 0001562180-24-000402 · primarydocument.xml · nonDerivative · entry 2 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,441 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 02:17 UTC |
Lurker NancyDirector · Executive Vice Chair
|
Exercise / conversionCommon Stock | 75,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000402 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 02:04 UTC |
Elston GeorgeChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 15,285 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000397 · primarydocument.xml · derivative · entry 5 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,570 Underlying: Common Stock · 15,285 shares Expires 2033-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning January 6, 2024. Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 02:04 UTC |
Elston GeorgeChief Financial Officer
|
Tax withholdingCommon Stock | 4,911 | $20.40 | $100,184.40 |
DisclosureSEC source: 0001562180-24-000397 · primarydocument.xml · nonDerivative · entry 2 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,308 F2 · price: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 02:04 UTC |
Elston GeorgeChief Financial Officer
|
Exercise / conversionCommon Stock | 15,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000397 · primarydocument.xml · nonDerivative · entry 1 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,818 shares acquired on January 31, 2023 pursuant to EyePoint's 2019 Employee Stock Purchase Plan. Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 02:28 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 15,285 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000403 · primarydocument.xml · derivative · entry 5 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,570 Underlying: Common Stock · 15,285 shares Expires 2033-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning January 6, 2024. Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 02:28 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Tax withholdingCommon Stock | 4,487 | $20.40 | $91,534.80 |
DisclosureSEC source: 0001562180-24-000403 · primarydocument.xml · nonDerivative · entry 2 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,505 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 02:28 UTC |
Paggiarino Dario A.Chief Medical Officer
|
Exercise / conversionCommon Stock | 15,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000403 · primarydocument.xml · nonDerivative · entry 1 Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 02:11 UTC |
Pine Michael CraigChief Corp Dev.&Strat. Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 15,285 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000400 · primarydocument.xml · derivative · entry 5 Pine Michael Craig · CIK 0001904458 · Chief Corp Dev.&Strat. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,570 Underlying: Common Stock · 15,285 shares Expires 2033-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning January 6, 2024. Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 02:11 UTC |
Pine Michael CraigChief Corp Dev.&Strat. Officer
|
Tax withholdingCommon Stock | 5,966 | $20.40 | $121,706.40 |
DisclosureSEC source: 0001562180-24-000400 · primarydocument.xml · nonDerivative · entry 2 Pine Michael Craig · CIK 0001904458 · Chief Corp Dev.&Strat. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,662 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 02:11 UTC |
Pine Michael CraigChief Corp Dev.&Strat. Officer
|
Exercise / conversionCommon Stock | 15,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000400 · primarydocument.xml · nonDerivative · entry 1 Pine Michael Craig · CIK 0001904458 · Chief Corp Dev.&Strat. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,628 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 02:07 UTC |
Duker Jay S.Director · President and CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 20,793 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000398 · primarydocument.xml · derivative · entry 5 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,587 Underlying: Common Stock · 20,793 shares Expires 2033-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning January 6, 2024. Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 02:07 UTC |
Duker Jay S.Director · President and CEO
|
Tax withholdingCommon Stock | 6,528 | $20.40 | $133,171.20 |
DisclosureSEC source: 0001562180-24-000398 · primarydocument.xml · nonDerivative · entry 2 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,486 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 02:07 UTC |
Duker Jay S.Director · President and CEO
|
Exercise / conversionCommon Stock | 20,793 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000398 · primarydocument.xml · nonDerivative · entry 1 Duker Jay S. · CIK 0001630864 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 20:53 UTC |
ANDO GORANDirector
|
GrantStock Option (Right to Buy) · Derivative | 23,598 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001562180-24-000392 · primarydocument.xml · derivative · entry 1 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,598 Underlying: Common Stock · 23,598 shares Expires 2034-01-04 Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:09 UTC |
Jones David ScottSVP & Chief Commercial Officer
|
GrantStock Option (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001562180-24-000399 · primarydocument.xml · derivative · entry 4 Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2034-01-04 F4 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 5th, 2025 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:09 UTC |
Jones David ScottSVP & Chief Commercial Officer
|
GrantRestricted Stock Units · Derivative | 21,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000399 · primarydocument.xml · derivative · entry 3 Jones David Scott · CIK 0001779458 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2034-01-05 F3 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 5, 2025. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 20:55 UTC |
Landis John B.Director
|
GrantStock Option (Right to Buy) · Derivative | 25,014 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001562180-24-000395 · primarydocument.xml · derivative · entry 3 Landis John B. · CIK 0001477283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,014 Underlying: Common Stock · 25,014 shares Expires 2034-01-04 Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 20:55 UTC |
Landis John B.Director
|
GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001562180-24-000395 · primarydocument.xml · derivative · entry 2 Landis John B. · CIK 0001477283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-01-04 Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 20:55 UTC |
Landis John B.Director
|
GrantRestricted Stock Units · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000395 · primarydocument.xml · derivative · entry 1 Landis John B. · CIK 0001477283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-01-04 Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 02:17 UTC |
Lurker NancyDirector · Executive Vice Chair
|
GrantStock Option (Right to Buy) · Derivative | 77,000 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001562180-24-000402 · primarydocument.xml · derivative · entry 4 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2034-01-04 F3 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 5th, 2025 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 02:17 UTC |
Lurker NancyDirector · Executive Vice Chair
|
GrantRestricted Stock Units · Derivative | 38,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000402 · primarydocument.xml · derivative · entry 3 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2034-01-05 F2 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 5, 2025. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 02:04 UTC |
Elston GeorgeChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001562180-24-000397 · primarydocument.xml · derivative · entry 4 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2034-01-04 F4 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 5th, 2025 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 02:04 UTC |
Elston GeorgeChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 45,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000397 · primarydocument.xml · derivative · entry 3 Elston George · CIK 0001429932 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-01-05 F3 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 5, 2025. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 20:54 UTC |
DICICCO WENDY FDirector
|
GrantStock Option (Right to Buy) · Derivative | 25,014 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001562180-24-000393 · primarydocument.xml · derivative · entry 1 DICICCO WENDY F · CIK 0001225165 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,014 Underlying: Common Stock · 25,014 shares Expires 2034-01-04 Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 20:56 UTC |
GUYER DAVID RDirector
|
GrantStock Option (Right to Buy) · Derivative | 25,014 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001562180-24-000396 · primarydocument.xml · derivative · entry 1 GUYER DAVID R · CIK 0001277476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,014 Underlying: Common Stock · 25,014 shares Expires 2034-01-04 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.